Sort
48,018 grants matching “immunotherapy”
Antigen-Presenting Cell Control of CD8+ T Cell Exhaustion in Cancer
$542,252Ming Li · Sloan-Kettering Inst Can Research · R01 · FY2025 · CA
Preclinical Development of First-in-Class GSTO1 Degraders for Colorectal Cancer
$542,198Nouri Neamati · University Of Michigan At Ann Arbor · R01 · FY2022 · CA
Immune Enhancement and Therapy of Cancer
$542,182University Of California San Francisco · U01 · FY2004 · CA
Posttranscriptional control of gene expression
$542,160Barbara Felber · Division Of Basic Sciences - Nci · ZIA · FY2013 · CA
Development of multifunctional drug and immune modulator delivery nanoparticles for the treatment of cancer patients with comorbid atherosclerosis
$542,085Lily Yang · Emory University · R01 · FY2021 · CA
Advancing T cell Therapy for Ovarian Cancer
$542,075George Coukos · Fox Chase Cancer Center · P50 · FY2010 · CA
Lymph node-targeted multistage chemoimmunotherapy for lymphoma
$542,074Susan Napier Thomas · Georgia Institute Of Technology · R01 · FY2020 · CA
Notch Signaling in the Adult Lymphatic Vasculature
$542,024Carrie J. Shawber · Columbia University Health Sciences · R01 · FY2025 · HL
Manipulating normal estrogen physiology as a therapeutic approach in cancer
$542,002Donald P McDonnell · Duke University · R01 · FY2025 · CA
Development of a novel therapy targeting the tumor microenvironment in inflammatory breast cancer
$541,958Naoto T Ueno · University Of Hawaii At Manoa · R01 · FY2024 · CA
Targeting Effector Immune cells to Cancer with Chemically Self-Assembled Nanorings (CSANs)
$541,946Carston R. Wagner · University Of Minnesota · R01 · FY2024 · CA
Epigenetic regulation of early B cell differentiation
$541,941Jeremy M. Boss · Emory University · R01 · FY2024 · AI
Epigenetic regulation of early B cell differentiation
$541,941Jeremy M. Boss · Emory University · R01 · FY2025 · AI
CD79A as a molecular switch regulating B cell activation
$541,908Andrew Getahun · University Of Colorado Denver · R01 · FY2025 · AI
CD79A as a molecular switch regulating B cell activation
$541,908Andrew Getahun · University Of Colorado Denver · R01 · FY2024 · AI
Integrated Discovery Pipeline for Tumor Neoantigens
$541,899Beatriz M. Carreno · University Of Pennsylvania · R01 · FY2020 · CA
Elucidating genetics of response to immune checkpoint blockade in lung cancer
$541,884Naiyer A Rizvi · Columbia University Health Sciences · R01 · FY2019 · CA
A NANOPARTICLE-BASED APPROACH FOR BREAST CANCER IMMUNOTHERAPY
$541,875Institut De Recherches Cliniques De Montreal · · FY2009 · Department of the Army
Understanding how adrenergic signaling influences immune contexture of tumors and the efficacy of checkpoint inhibitors
$541,844Elizabeth Repasky · Roswell Park Cancer Institute Corp · R01 · FY2019 · CA
Targeting convergent oncogenic signaling during AR inhibition to overcome metastasis and immune evasion in prostate cancer
$541,779Andrew J Armstrong · Duke University · R01 · FY2020 · CA
Tumor-barcoding coupled with high-throughput sequencing for quantitative radiogenomics of the abscopal response in NSCLC
$541,670Phuoc T. Tran · University Of Maryland Baltimore · R01 · FY2023 · CA
Modulation of Host Responses by Mycobacterium tuberculosis
$541,546Jyothi Rengarajan · Emory University · R56 · FY2016 · AI
Activation of Human Natural Killer Cell Function
$541,439Eric O Long · National Institute Of Allergy And Infectious Diseases · ZIA · FY2016 · AI
Mechanisms of PD-1 and Tim-3 crosstalk in tumor-infiltrating lymphocytes
$541,414Lawrence P Kane · University Of Pittsburgh At Pittsburgh · R01 · FY2025 · CA
Mechanisms of PD-1 and Tim-3 crosstalk in tumor-infiltrating lymphocytes
$541,414Lawrence P Kane · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · CA